全文获取类型
收费全文 | 32164篇 |
免费 | 3160篇 |
国内免费 | 2334篇 |
专业分类
耳鼻咽喉 | 262篇 |
儿科学 | 582篇 |
妇产科学 | 259篇 |
基础医学 | 1885篇 |
口腔科学 | 721篇 |
临床医学 | 4057篇 |
内科学 | 2608篇 |
皮肤病学 | 245篇 |
神经病学 | 730篇 |
特种医学 | 1289篇 |
外科学 | 3246篇 |
综合类 | 8848篇 |
现状与发展 | 8篇 |
预防医学 | 3856篇 |
眼科学 | 316篇 |
药学 | 4138篇 |
54篇 | |
中国医学 | 3263篇 |
肿瘤学 | 1291篇 |
出版年
2024年 | 185篇 |
2023年 | 461篇 |
2022年 | 1062篇 |
2021年 | 1272篇 |
2020年 | 1176篇 |
2019年 | 568篇 |
2018年 | 642篇 |
2017年 | 913篇 |
2016年 | 781篇 |
2015年 | 1313篇 |
2014年 | 1649篇 |
2013年 | 2133篇 |
2012年 | 3075篇 |
2011年 | 3234篇 |
2010年 | 2847篇 |
2009年 | 2583篇 |
2008年 | 2644篇 |
2007年 | 2478篇 |
2006年 | 2293篇 |
2005年 | 1655篇 |
2004年 | 1238篇 |
2003年 | 1019篇 |
2002年 | 756篇 |
2001年 | 752篇 |
2000年 | 536篇 |
1999年 | 152篇 |
1998年 | 38篇 |
1997年 | 20篇 |
1996年 | 23篇 |
1995年 | 36篇 |
1994年 | 29篇 |
1993年 | 11篇 |
1992年 | 10篇 |
1991年 | 14篇 |
1990年 | 11篇 |
1989年 | 3篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 9篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1966年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
目的探讨中药黄柏粉配合红霉素治疗子宫颈炎的临床效果。方法选择144例子宫颈炎患者,随机分为治疗组、对照组各72例,治疗组应用中药黄白粉配合红霉素进行治疗,对照组应用消糜灵栓;比较两组的临床治愈率。结果治疗组的急性宫颈炎及各度宫颈糜烂治愈率均较对照组高,差异有统计学意义(P<0.05)。结论黄柏粉配合红霉素治疗子宫颈炎具有良好效果,值得临床推广应用。 相似文献
993.
994.
多囊卵巢综合征(PCOS)是育龄妇女常见的内分泌性疾病,跨越了妇女生命的全过程,以高胰岛素血症、高雄激素血症和(或)无排卵为特征,目前病因尚不明确,然而胰岛素抵抗(IR)是PCOS患者常见的代谢紊乱性疾病。由此产生的高胰岛素血症可导致激素水平改变、卵泡生长受限、子宫内膜容受性改变,增加流产率或导致不孕等,同时可增加妊娠合并症的发病率,甚至让患者产生焦虑、抑郁等心理问题,因此PCOS伴IR越来越受到人们的重视。阐述PCOS伴IR对生育影响的研究进展。 相似文献
995.
目的观察小剂量阿托品对急性右冠状动脉梗塞急诊冠状动脉(简称冠脉)介入治疗术中再灌注心律失常的影响。方法 128例冠脉造影显示急性右冠脉闭塞致心肌梗死(简称心梗)患者,分为阿托品组(66例)和对照组(62例),阿托品组冠脉开通前给予小剂量阿托品0.5 mg静脉注射,对照组不给予阿托品干预,观察两组再灌注心律失常发生情况。结果阿托品组发生再灌注心律失常27例,其中快速心律失常16例,缓慢心律失常11例,术后低血压13例,对照组发生再灌注心律失常47例,其中快速心律失常15例,缓慢心律失常32例,术后低血压24例,两组缓慢性心律失常和低血压发生率有显著差异(P<0.05),而两组快速心律失常发生率无统计学差异。结论对急性右冠脉心梗患者,急诊开通冠脉前,给予小剂量阿托品可以减少再灌注引起的缓慢性心律失常及低血压的发生率。 相似文献
996.
997.
目的 对比观察奥沙利铂联合氟尿嘧啶和亚叶酸钙方案(FOLFOX4)治疗70岁及以上转移性结直肠癌患者与70岁以下患者的不良反应和疗效.方法 61例转移性结直肠癌患者,其中≥70岁组28例,<70岁组33例,两组患者均接受FOLFOX4方案化疗,14 d为1个周期,治疗期间观察不良反应,3个周期后评价疗效.结果 61例患者均可评价不良反应及疗效.主要不良反应为骨髓抑制、胃肠道反应及神经毒性,≥70岁组腹泻的发生率高于<70岁组,但主要为1~2度不良反应.≥70岁组白细胞和中性粒细胞下降的发生率高于<70岁组(92.8%比78.8%和39.3%比36.3%),但差异无统计学意义.≥70岁组神经系统毒性发生率为46.5%,<70岁组为36.4%,均为1~2度,两组间差异无统计学意义.≥70岁组患者近期有效率为25%,疾病控制率为71.4%,中位疾病进展时间(TTP)为6个月,<70岁组患者近期有效率24.2%,疾病控制率84.8%,中位TTP 7个月,两组有效率和疾病控制率差异无统计学意义,而<70岁组患者的中位TTP比≥70岁组略长.结论FOLFOX4方案同样适用于≥70岁转移性结直肠癌患者,其耐受性较好且疗效肯定.Abstract: Objective To observe the safety and efficacy of FOLFOX4 regiment in elderly versus young patients with advanced colorectal cancer. Methods There were 61 patients enrolled in this study, with 28 elderly patients aged 70 years and over, 33 young patients aged less than 70 years.They suffered from advanced/recurrent colorectal cancer and received FOLFOX4 regiment (Oxaliplatin +CF+5-FU). Every 14 days were as a cycle, and the therapeutic safety and efficacy were evaluated after three cycles. Adverse events and response to treatment were compared between the elderly and young patients. Results The main adverse effects were myelosuppression, gastrointestinal disturbance and neurotoxicity. The incidence rate of diarrhea was significantly higher in elderly patients than in young patients, but the most of diarrhea were at grade Ⅰ - Ⅱ. The incidence rates of leucocyte decrease and neutrophil decrease were higher in elderly patients than in young patients (92. 8% vs. 78. 8%, 39.3% vs. 36.3%), but there were no statistically significant differences between them. The incidence rate of neurotoxicity was 46.5% in elderly patients and 36.4% in young patients (P>0. 05). The recent efficacy rate was 25%, disease control rate was 71.4% and median time-to-progression (TTP) was 6 months in elderly patients and 24.2%, 84.8% and 7 months in young patients (all P>0.05). Conclusions FOLFOX4 regiment is well-tolerated and effective in both young and elderly patients. 相似文献
998.
<正> 多房性囊性肾瘤是一种较少见的肾脏囊性病变,国内外文献报道较少。笔者回顾性分析2例多房性囊性肾瘤的CT表现,同时复习相关文献,以总结其影像表现。1 临床资料例1:女,41岁,体检发现左肾病变,查体未见明显异常。实验室检查:血、尿常规及肝、肾功能均无异常。 相似文献
999.
Objective To investigate the role of surfactant protein (SP) - A and SP - D in urinary tract infection mouse model, and evaluate the effects of SP-A and SP-D absence on urinary tract infection. Methods SP-A and SP-D double knockout (SP-A/D KO) mice were made. SP-A/D KO and wild-type (WT) C57BL/6 female mice were used for this study. The expression of SP-A and SP-D in kidney was detected by immunohistochemistry (IHC). The levels of p - p38 and p38 protein in kidneys were measured by Western blotting. Uropathogenic Escherichia coli or buffer was delivered into the bladder of female mice. At 24 and 48 h after inoculation, CFU of Escherichia coli in the kidney and urine of the treated and control mice were measured. Histological, cellular and molecular analysis were performed by several methods of H/E staining, IHC and Western blotting. The effects of SP-A and SP-D on bacterial growth were studied in vitro. Results SP-A and SP-D in kidney were located in the proximal tubules and collecting tubules. Compared with WT mice, infected SP - A/D KO mice with UPEC had higher CFU in kidneys and urine at 24 h and 48 h, increased inflammatory cells infiltration in kidneys(P<0.05). Compared with WT mice, SP - A/D KO mice had higher p38 MAPK phosphorylation levels in kidneys(P<0.05). Growth of Escherichia coli was greatly inhibited by both SP-A and SP-D(P<0.05). Conclusions Both SP-A and SP-D are expressed in kidney. SP-A and SP-D can attenuate UTI induced by UPEC which may be through inhibiting bacterial growth and modulating renal inflammation. 相似文献
1000.